Revenue Growth - Net revenue for Q3 2024 increased by 13.3% to $702.5 million compared to $620.0 million in Q3 2023, driven by growth in Generics, AvKARE, and Specialty segments [184][185]. - Generics segment net revenue rose by 9.3% to $427.3 million, with new product launches contributing $34.8 million and biosimilars adding $5.7 million to year-over-year growth [196][197]. - Specialty net revenue for Q3 2024 increased by 18.8% to $115.6 million, primarily due to a $16.8 million increase in the promoted Parkinson's franchise [203]. - AvKARE net revenue for Q3 2024 increased by 20.9% to $159.5 million, driven by growth in distribution and government label channels [210]. - Total net revenue for the nine months ended September 30, 2024 increased by 16.1% to $2.06 billion, primarily due to growth in Generics, AvKARE, and Specialty segments [214]. - Generics net revenue for the nine months ended September 30, 2024 increased by 12.4% to $1,245,967, primarily driven by new generic product launches and strong volume growth [228]. - Specialty net revenue for the nine months ended September 30, 2024 increased by 13.6% to $324,913, driven by growth in the promoted Parkinson's franchise and endocrinology portfolio [237]. - AvKARE net revenue for the nine months ended September 30, 2024 increased by 28.8% to $492,559, primarily due to growth in distribution and government label channels [243]. Profitability and Margins - Gross profit margin improved to 38.4% in Q3 2024 from 37.5% in Q3 2023, reflecting effective cost management despite rising costs [189]. - Specialty gross profit as a percentage of net revenue rose to 54.7% in Q3 2024 from 53.2% in the prior year, attributed to higher margin promoted products [205]. - AvKARE gross profit as a percentage of net revenue decreased to 17.7% in Q3 2024 from 19.9% in the prior year, due to increased sales through lower margin channels [211]. - Gross profit for the Generics segment increased by 19.1% to $495,800, with gross profit as a percentage of net revenue rising to 39.8% from 37.6% [230]. - Specialty gross profit as a percentage of net revenue increased to 55.9% from 52.7%, reflecting growth in higher margin promoted products [238]. Expenses and Costs - Research and development expenses surged by 47.7% to $61.1 million, largely due to increased in-licensing and milestone payments totaling $23.8 million [191]. - Cost of goods sold increased by 11.7% to $432.9 million, attributed to higher volumes and increased plant and freight costs [188]. - Total other expense rose by 39.3% to $73.4 million, primarily due to a $14.6 million increase in interest expense [193]. - R&D expenses for the nine months ended September 30, 2024 increased by 15.8% to $136.4 million, mainly due to in-licensing and milestone payments [221]. - SG&A expenses for the nine months ended September 30, 2024 increased by 8.4% to $347.7 million, driven by employee compensation and promotional costs [220]. - Charges related to legal matters for the nine months ended September 30, 2024 amounted to $94.9 million, primarily associated with opioid litigation settlements [222]. Cash Flow and Liquidity - Net cash provided by operating activities decreased to $177.0 million for the nine months ended September 30, 2024, down from $209.8 million in the prior year, reflecting a decrease of 15.6% [257]. - Net cash used in investing activities increased to $46.9 million in 2024 from $37.5 million in 2023, primarily due to a $9.5 million sales-based milestone payment [258]. - Net cash used in financing activities rose to $150.6 million in 2024 compared to $111.7 million in 2023, with total debt repayments increasing to $127.3 million [259]. - The net decrease in cash, cash equivalents, and restricted cash was $20.8 million for the nine months ended September 30, 2024, compared to an increase of $60.4 million in the prior year, representing a change of 134.4% [256]. - The company reported a decrease in collections of outstanding accounts receivable, impacting cash flows from operating activities [257]. - The company reported favorable working capital movements, notably an increase in days payables outstanding, which partially offset cash flow declines [257]. - As of September 30, 2024, the company has access to $455.2 million under the Amended New Revolving Credit Facility, ensuring sufficient liquidity for planned operations [245]. Strategic Developments - The FDA approved CREXONT® on August 7, 2024, with sales commencing in September 2024, enhancing the Specialty segment's portfolio [177]. - The company expects to invest approximately $60.0 million to $70.0 million in capital expenditures during 2024 to support and grow existing operations [246]. - The company acquired a 65.1% controlling interest in AvKARE, LLC and R&S, with cash tax distributions to sellers amounting to $14.4 million in 2024 and $10.3 million in 2023 [253]. - Generics R&D expenses for Q3 2024 increased by 62.7% year-over-year, driven by in-licensing and upfront milestone payments totaling $23.8 million [200]. - There were no material changes in the company's internal control over financial reporting as of September 30, 2024 [265].

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President & Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer, Specialty Conference Call Participants David Amsellem - Piper Sandler Balaji Prasad - Barclays Bank Leszek Sulewski - Tr ...

Revenue Performance - Q3 2024 net revenue was $702 million, a 13% increase compared to $620 million in Q3 2023[3] - Net revenue for Q3 2024 increased to $702.5 million, up 13.3% from $620.0 million in Q3 2023[17] - Generics net revenue increased 9% driven by strong performance of new product launches and biosimilars[3] - Specialty net revenue increased 19% driven by promoted products in neurology and endocrinology, including the recent launches of CREXONT and ONGENTYS for Parkinson's disease[3] - AvKARE net revenue increased 21% driven by growth across its distribution and government label sales channels[3] - Generics segment net revenue for Q3 2024 was $427.3 million, a 9.3% increase from $390.9 million in Q3 2023[31] - Specialty segment net revenue for Q3 2024 was $115.6 million, an 18.8% increase from $97.3 million in Q3 2023[38] - Generics segment nine-month net revenue for 2024 was $1.25 billion, a 12.4% increase from $1.11 billion in 2023[34] - Specialty segment nine-month net revenue for 2024 was $324.9 million, a 13.6% increase from $285.9 million in 2023[40] - Net revenue for the three months ended September 30, 2024 was $159.485 million, compared to $131.879 million in the same period in 2023[42] - Net revenue for the nine months ended September 30, 2024 was $492.559 million, compared to $382.286 million in the same period in 2023[44] Profitability and Margins - Gross profit for Q3 2024 rose to $269.6 million, a 15.9% increase from $232.5 million in Q3 2023[17] - Operating income for Q3 2024 grew to $88.8 million, up 17.4% from $75.6 million in Q3 2023[17] - Generics segment gross margin improved to 44.3% in Q3 2024 from 43.0% in Q3 2023[31] - Specialty segment gross margin increased to 80.2% in Q3 2024 from 79.7% in Q3 2023[38] - Gross margin for the three months ended September 30, 2024 was 17.7%, down from 19.9% in the same period in 2023[42] - Gross margin for the nine months ended September 30, 2024 was 16.3%, down from 16.7% in the same period in 2023[44] - Operating income for the three months ended September 30, 2024 was $16.659 million, up from $15.533 million in the same period in 2023[42] - Operating income for the nine months ended September 30, 2024 was $46.078 million, up from $34.001 million in the same period in 2023[44] Segment Performance - Generics segment operating income for Q3 2024 was $102.2 million, a 3.9% decrease from $106.3 million in Q3 2023[31] - Specialty segment operating income for Q3 2024 was $61.2 million, a 24.5% increase from $49.2 million in Q3 2023[38] - Generics segment nine-month operating income for 2024 was $315.5 million, a 10.2% increase from $286.2 million in 2023[34] - Specialty segment nine-month operating income for 2024 was $171.5 million, a 19.7% increase from $143.3 million in 2023[40] Financial Position - Total current assets as of September 30, 2024, increased to $1.51 billion from $1.38 billion as of December 31, 2023[19] - Long-term debt decreased to $2.17 billion as of September 30, 2024, from $2.39 billion as of December 31, 2023[19] - Trade accounts receivable, net, increased to $748.1 million as of September 30, 2024, from $613.7 million as of December 31, 2023[19] - Total liabilities as of September 30, 2024, were $3.46 billion, slightly down from $3.47 billion as of December 31, 2023[19] - Cash and cash equivalents decreased to $74.0 million as of September 30, 2024, from $91.5 million as of December 31, 2023[19] Earnings and Losses - Diluted loss per share in Q3 2024 was $0.00 compared to diluted income per share of $0.06 in Q3 2023[5] - Adjusted diluted EPS in Q3 2024 was $0.16 compared to $0.19 in Q3 2023[5] - Net loss attributable to Amneal Pharmaceuticals for Q3 2024 was $0.2 million, compared to a net income of $9.7 million in Q3 2023[17] - Net loss for the nine months ended September 30, 2024 was $53.1 million, compared to a net income of $44.6 million in the same period of 2023[21] - Adjusted diluted earnings per share for the nine months ended September 30, 2024 was $0.46, compared to $0.50 in the same period of 2023[24] Research and Development - Research and development expenses for Q3 2024 increased to $61.1 million, up 47.7% from $41.4 million in Q3 2023[17] - The company launched CREXONT for the treatment of Parkinson's disease and announced a collaboration with Metsera, Inc. for next-generation medicines for obesity and metabolic diseases[2] - The company expanded its pipeline by in-licensing a new high-value biosimilar[2] Adjusted EBITDA and Cash Flow - Adjusted EBITDA in Q3 2024 was $158 million, a 2% increase compared to Q3 2023, partially offset by a $20 million R&D milestone payment[4] - Adjusted EBITDA for the nine months ended September 30, 2024 was $472.2 million, an increase from $416.1 million in the same period of 2023[23] - Net cash provided by operating activities for the nine months ended September 30, 2024 was $177.0 million, a decrease from $209.8 million in the same period of 2023[21] Expenses and Adjustments - Depreciation and amortization expenses for the nine months ended September 30, 2024 were $170.1 million, slightly lower than $172.5 million in the same period of 2023[21] - Inventory provision for the nine months ended September 30, 2024 was $63.6 million, an increase from $56.6 million in the same period of 2023[21] - Charges related to legal matters for the nine months ended September 30, 2024 were $94.9 million, primarily associated with a nationwide opioid settlement[27] - Non-GAAP effective tax rate for the nine months ended September 30, 2024 was 24.7%, compared to 21.6% in the same period of 2023[28] - System implementation expenses for the nine months ended September 30, 2024 were $2.0 million, primarily for integrating acquired businesses[28] - Adjustments for the three months ended September 30, 2024 included $3.5 million in amortization expense[43] - Adjustments for the nine months ended September 30, 2024 included $10.6 million in amortization expense[45] Full-Year Guidance - Full-year 2024 guidance includes net revenue of $2.70 billion to $2.80 billion, adjusted EBITDA of $610 million to $630 million, and adjusted diluted EPS of $0.57 to $0.63[6]

Revenue Growth - Net revenue for the three months ended June 30, 2024, increased by 17.1% to $701.8 million compared to $599.0 million in the prior year period[195] - The Generics segment net revenue grew by $53.6 million, driven by new product launches, including biosimilars contributing $16.7 million and other new generics contributing $36.2 million[197] - The AvKARE segment net revenue increased by $42.1 million, primarily due to growth in distribution and government label channels from new product introductions[197] - The Specialty segment net revenue increased by $7.0 million, primarily due to a $9.4 million rise in the neurology portfolio, including $3.5 million from ONGENTYS® sales[197] - Net revenue for the three months ended June 30, 2024, increased by 7.3% to $104.041 million, driven by a $9.4 million increase in the promoted neurology portfolio[214] - Consolidated net revenue for the six months ended June 30, 2024, increased by 17.7% to $1.360 billion, primarily due to growth in the Generics segment[226] - Generics net revenue increased by 14.1% to $818.622 million, driven by new generic product launches and strong volume growth[238] - Specialty net revenue rose by 10.9% to $209.3 million for the six months ended June 30, 2024, driven by a $18.8 million increase in the neurology portfolio[245] - AvKARE net revenue surged by 33.0% to $333.1 million for the six months ended June 30, 2024, primarily due to growth in distribution channels[253] Profitability - Gross profit for the three months ended June 30, 2024, was $249.9 million, with a gross profit margin of 35.6%, down from 36.7% in the prior year[198] - Gross profit as a percentage of net revenue increased to 55.7% for the three months ended June 30, 2024, compared to 52.0% in the prior year period[215] - Generics gross profit margin improved to 38.8% for the six months ended June 30, 2024, up from 36.5% in the prior year[239] - Specialty gross profit margin increased to 56.5% for the six months ended June 30, 2024, compared to 52.5% in the prior year[246] - AvKARE gross profit margin improved to 15.6% for the six months ended June 30, 2024, up from 15.0% in the prior year[254] Expenses - Selling, general, and administrative expenses rose by 10.3% to $116.5 million, mainly due to increased employee compensation and promotional costs related to new product launches[199] - Research and development expenses decreased by 4.6% to $36.1 million, attributed to lower in-licensing and milestone payments[200] - Specialty SG&A expenses increased by 16.9% to $26.610 million, primarily due to promotional costs associated with ONGENTYS®[216] - R&D expenses decreased by 35.0% to $4.351 million, attributed to reduced project spending and infrastructure costs[217] - Generics SG&A expenses increased by 16.3% for the six months ended June 30, 2024, mainly due to employee compensation related to infrastructure expansion[240] - Specialty R&D expenses decreased by 28.8% to $9.3 million for the six months ended June 30, 2024, due to reduced project spending[248] Other Financial Metrics - Total other expense increased by 48.9% to $75.1 million, driven by a $14.9 million rise in interest expense and a $13.0 million increase in tax receivable agreement liability[202] - The provision for income taxes for the three months ended June 30, 2024, was $3.6 million, with an effective tax rate of 17.7%[203] - Total other expense for the six months ended June 30, 2024, increased by 48.3% to $(139.841) million, primarily due to higher interest expenses[233] - Charges related to legal matters for the six months ended June 30, 2024, amounted to $95.1 million, primarily associated with opioid-related settlements[232] Cash Flow and Capital Expenditures - Net cash provided by operating activities decreased to $35.2 million for the six months ended June 30, 2024, down 72.5% from $128.4 million in the prior year period[268] - Net cash used in investing activities increased to $26.2 million for the six months ended June 30, 2024, compared to $24.0 million in the prior year period, reflecting a rise of 9.2%[269] - Net cash used in financing activities rose significantly to $58.2 million for the six months ended June 30, 2024, an increase of 131.5% from $25.2 million in the prior year period[270] - The decrease in net operating cash flows was primarily due to lower collections of accounts receivable and the absence of a $21.4 million upfront payment received in the prior year[268] - The increase in cash used in investing activities was mainly due to a sales-based milestone payment related to a licensing agreement, partially offset by proceeds from the sale of a subsidiary[269] - The increase in cash used in financing activities was driven by a decrease in net debt of $55.1 million and increased payroll tax withholding on restricted stock units[270] - The company estimates capital expenditures of approximately $60.0 million to $70.0 million during 2024 to support operations[256] Company Outlook and Other Information - The Company expects to launch CREXONT®, a new drug for Parkinson's disease, in September 2024 following FDA approval[188] - As of June 30, 2024, there were no material changes to the company's contractual obligations as disclosed in the 2023 Annual Report[271] - The company reported no off-balance sheet arrangements as of June 30, 2024[272] - There have been no material changes in the company's assessment of market risk as outlined in the 2023 Annual Report[274] - The company has not disclosed any recently issued accounting standards that would materially affect its financial condition[274] - The company has access to $416.9 million under the Amended New Revolving Credit Facility as of June 30, 2024, which is deemed sufficient for planned operations[255]

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q2 2024 Earnings Conference Call August 9, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President & Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer, Specialty Conference Call Participants David Amsellem - Piper Sandler Leszek Sulewski - Truist Securities Operator Good mo ...

Exhibit 99.2 AMNEAL REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS ‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Raising 2024 Full Year Guidance ‒ ‒ CREXONT U.S. FDA approval represents an exciting new long-term growth driver ‒ ® BRIDGEWATER, NJ, August 9, 2024 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") announced its results today for the second quart ...

Financial Performance - Net revenue for the three months ended March 31, 2024, increased by 18.2% to $659.2 million compared to $557.5 million in the prior year period[188]. - Gross profit increased by 33.6% to $238.1 million, with a gross profit margin of 36.1%, up from 32.0% in the prior year[188][191]. - The net loss for the three months ended March 31, 2024, was $81.7 million, compared to a net loss of $10.1 million in the prior year[188]. Segment Performance - The Generics segment net revenue grew by $47.5 million, primarily due to new product launches, including biosimilars contributing $24.6 million[192]. - The AvKARE segment net revenue increased by $40.6 million, driven by growth in distribution and government label channels[192]. - The Specialty segment net revenue rose by $13.6 million, with $4.0 million from ONGENTYS® sales, which launched in Q1 2024[193]. - Generics net revenue for Q1 2024 increased by 13.8% year-over-year, driven by new generic product launches contributing $24.6 million and $19.2 million, respectively[202]. - Specialty net revenue for Q1 2024 rose by 14.8% compared to the prior year, with a $9.4 million increase in the neurology portfolio, including $4.0 million from ONGENTYS®[209]. - AvKARE net revenue for Q1 2024 increased by 33.3% year-over-year, primarily due to growth in distribution and government label channels[216]. Expenses - Research and development expenses increased by 1.6% to $39.3 million, primarily due to higher in-licensing and milestone payments[195]. - Selling, general, and administrative expenses rose by 10.3% to $112.6 million, mainly due to increased employee compensation and promotional activities[192]. - Generics SG&A expenses increased by 19.9% in Q1 2024, mainly due to higher employee compensation and promotional costs related to biosimilars[204]. - Specialty R&D expenses decreased by 22.2% in Q1 2024, primarily due to reduced project spending and infrastructure costs[212]. Litigation and Charges - A charge of $94.4 million was recorded for Generics civil prescription opioid litigation in Q1 2024, compared to a net credit of $0.4 million in Q1 2023[197]. - The company recorded a charge of $94.4 million related to civil prescription opioid litigation in Q1 2024[206]. - A settlement in principle was reached in April 2024 regarding nationwide civil prescription opioid litigation, with no admission of wrongdoing[222]. Cash Flow and Investments - Net cash used in operating activities was $4.4 million for Q1 2024, a decrease of 103.2% compared to $139.7 million in Q1 2023[231]. - Net cash used in investing activities increased to $19.8 million in Q1 2024 from $11.7 million in Q1 2023, representing a 68.4% increase[232]. - Net cash used in financing activities was $23.2 million for Q1 2024, up 79.5% from $12.9 million in Q1 2023[233]. - The overall net decrease in cash, cash equivalents, and restricted cash was $47.5 million in Q1 2024, compared to an increase of $115.8 million in Q1 2023[230]. - The decrease in operating cash flows was primarily due to lower collections of accounts receivable and the absence of a $21.4 million upfront payment received in Q1 2023[231]. - The increase in cash used in investing activities was primarily due to a sales-based milestone payment related to a licensing agreement[233]. - The increase in cash used in financing activities was driven by net payments of principal on debt and increased payroll tax withholding[233]. Financial Position and Risk - As of March 31, 2024, the company has access to $397.7 million under the Amended New Revolving Credit Facility and $28.0 million under the Amended Rondo Revolving Credit Facility[219]. - There were no material changes to contractual obligations or off-balance sheet arrangements as of March 31, 2024[234][235]. - There has been no material change in the assessment of market risk as disclosed in the 2023 Annual Report[238]. - Critical accounting policies and estimates remain unchanged from the disclosures in the 2023 Annual Report[236]. Capital Expenditures - The company expects to invest approximately $60.0 million to $70.0 million in capital expenditures during 2024 to support and grow existing operations[220].

Q1 2024 Earnings Call May 3, 2024 Cautionary Statement on Forward Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expe ...

Financial Data and Key Metrics Changes - Q1 2024 total net revenue reached $659 million, an 18% increase year-over-year [6][22] - Adjusted EBITDA for Q1 was $152 million, reflecting a 31% growth [6][23] - Adjusted EPS for Q1 was $0.14, up 17% compared to the previous year [24] Business Line Data and Key Metrics Changes - Generics segment net revenue was $391 million, growing 14% driven by a diverse portfolio [22] - Specialty segment net revenues reached $105 million, a 15% increase, supported by the launch of ONGENTYS [22] - AvKARE segment net revenues grew by 33% to $163 million, reflecting strong growth across all customer channels [23] Market Data and Key Metrics Changes - The company fills approximately 175 million prescriptions annually in the U.S., with a focus on complex generics and injectables [7] - The biosimilars market is expected to see significant growth, with an estimated $192 billion in annual branded biologics losing exclusivity from 2024 to 2028 [11] Company Strategy and Development Direction - The strategic vision is to be a global, diversified pharmaceutical company providing access to high-quality, affordable medicines [6] - The company is expanding its portfolio in biosimilars and injectables, with plans to launch over 30 new products in 2024 [10][11] - International expansion is a focus, with expectations to add $5.2 billion in revenues by 2027 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving financial commitments for 2024 and beyond, citing strong execution and growth momentum [6][24] - The recent approval of naloxone is seen as a significant step in addressing the opioid crisis, with plans to expand access through various channels [8][25] - The company is targeting the higher end of its full-year revenue outlook, expecting total net revenue of $2.55 billion to $2.65 billion [25] Other Important Information - The company has resolved legacy legal matters, including a nationwide opioid settlement, which is expected to alleviate financial overhangs [25] - The company has built capacity to supply up to 10 million units of naloxone starting next year [30] Q&A Session Summary Question: Can you talk about the California contract for naloxone? - The California contract starts now, with potential purchases of up to 3.2 million units per year, ramping up demand over time [28] Question: What is the earnings cadence for this year? - The company is focused on maximizing performance while also investing in R&D for long-term growth [33][34] Question: Can you provide an update on ONGENTYS and PEMRYDI? - Positive feedback has been received for ONGENTYS, and PEMRYDI is expected to drive growth as a ready-to-use oncology therapy [36][38] Question: What are the dynamics driving sales for ALYMSYS? - Strong sales are attributed to a well-established commercial team and a broader product portfolio that enhances negotiating power [49] Question: What is the potential for biosimilars Prolia and XGEVA? - Launches are expected in 2026, with good market penetration anticipated due to established relationships [62]

Financial Performance - Q1 2024 net revenue was $659 million, an 18% increase from $558 million in Q1 2023[3] - Adjusted EBITDA for Q1 2024 was $152 million, reflecting a 31% increase compared to Q1 2023[3] - The company reported a net loss of $92 million in Q1 2024, compared to a net loss of $7 million in Q1 2023, including a $94 million charge related to an opioids settlement[3][4] - Adjusted diluted EPS for Q1 2024 was $0.14, up from $0.12 in Q1 2023[4] - Net revenue for the three months ended March 31, 2024, was $659.2 million, a 18.2% increase from $557.5 million in the same period of 2023[23] - Gross profit for the same period was $238.1 million, compared to $178.2 million, reflecting a gross margin improvement[23] - Net loss attributable to Amneal Pharmaceuticals, Inc. was $91.6 million, significantly higher than the net loss of $6.9 million in the prior year[23] - Adjusted EBITDA for the three months ended March 31, 2024, was $152.4 million, up from $116.2 million in the same period of 2023[31] - Net loss for the three months ended March 31, 2024, was $81,678, compared to a net loss of $10,094 for the same period in 2023[34] - Adjusted net income (Non-GAAP) for the three months ended March 31, 2024, was $44,480, an increase from $36,811 in the prior year[34] - Adjusted diluted earnings per share (Non-GAAP) increased to $0.14 for the three months ended March 31, 2024, compared to $0.12 in the same period of 2023[34] Revenue Segments - Generics revenues increased by 14%, driven by strong performance in complex generics and oncology biosimilars[3] - Specialty revenues rose by 15%, supported by promoted products in Neurology and Endocrinology[3] - AvKARE revenues surged by 33% due to continued expansion and new product launches[3] - Net revenue for the Generics segment was $391,294 for the three months ended March 31, 2024, up from $343,806 in the prior year[41] - Specialty segment net revenue was $105,234 for the three months ended March 31, 2024, compared to $91,678 in the same period of 2023[44] - AvKARE segment net revenue reached $162,663 for the three months ended March 31, 2024, compared to $122,056 in the same period of 2023[48] Guidance and Projections - Full year 2024 guidance is affirmed, with net revenue expected between $2.55 billion and $2.65 billion[9] - Adjusted EBITDA guidance for 2024 is projected between $580 million and $620 million[9] Cash and Assets - Cash and cash equivalents decreased to $46.5 million from $91.5 million at the end of December 2023[26] - Total current assets slightly increased to $1.38 billion from $1.38 billion at the end of December 2023[26] - Total liabilities increased to $3.46 billion from $3.47 billion at the end of December 2023, with long-term debt remaining stable[26] - The company reported a significant increase in accounts payable and accrued expenses, rising to $558.5 million from $534.7 million[26] Research and Development - Research and development expenses were $39.3 million, compared to $38.7 million in the prior year, indicating continued investment in innovation[23] Legal Matters - Charges related to legal matters for the three months ended March 31, 2024, amounted to $94,486, significantly higher than $4,882 in the same period of 2023[34] - The company has reached a settlement in principle for a nationwide opioids settlement, involving $92.5 million in cash and $180 million in naloxone nasal spray over ten years[5]